BioCardia (BCDA) Liabilities and Shareholders Equity (2010 - 2026)

BioCardia (BCDA) has reported Liabilities and Shareholders Equity for 16 consecutive years, with $4.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 127.62% year-over-year to $4.8 million in Q2 2026; TTM through Jun 2026 was $16.0 million, a 12.51% increase from a year earlier, with the FY2025 full-year figure at $3.4 million, down 8.35% from the prior year.
• Liabilities and Shareholders Equity was $4.8 million for Q2 2026 at BioCardia, up from $1.7 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $12.8 million in Q1 2022 and troughed at $1.7 million in Q1 2026.
• A 5-year average of $5.5 million and a median of $4.3 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity tumbled 69.5% in 2023 and jumped 127.62% in 2026, its largest moves.
• Over 5 years, Liabilities and Shareholders Equity stood at $9.8 million in 2022, then plunged by 69.5% to $3.0 million in 2023, then gained by 24.67% to $3.7 million in 2024, then dropped by 8.35% to $3.4 million in 2025, then jumped by 39.32% to $4.8 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $4.8 million (Q2 2026), $1.7 million (Q1 2026), and $3.4 million (Q4 2025), per Business Quant data.